Cargando…
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
BACKGROUND: Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers (BCs). It is more commonly diagnosed in younger women and often has a less favorable prognosis compared with other BC subtypes. OBJECTIVE: The objective of this study was to provide a literature-based extensiv...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095534/ https://www.ncbi.nlm.nih.gov/pubmed/35112331 http://dx.doi.org/10.1007/s40273-021-01121-7 |
_version_ | 1784705774338965504 |
---|---|
author | Huang, Min Haiderali, Amin Fox, Grace E. Frederickson, Andrew Cortes, Javier Fasching, Peter A. O’Shaughnessy, Joyce |
author_facet | Huang, Min Haiderali, Amin Fox, Grace E. Frederickson, Andrew Cortes, Javier Fasching, Peter A. O’Shaughnessy, Joyce |
author_sort | Huang, Min |
collection | PubMed |
description | BACKGROUND: Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers (BCs). It is more commonly diagnosed in younger women and often has a less favorable prognosis compared with other BC subtypes. OBJECTIVE: The objective of this study was to provide a literature-based extensive overview of the economic and humanistic burden of TNBC to assist medical decisions for healthcare payers, providers, and patients. METHODS: A systematic literature review was performed using multiple databases, including EMBASE, MEDLINE, Econlit, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from database inception to 16 May 2021. In addition, a targeted search was performed in the Northern Light Life Sciences Conference Abstracts database from 2016 through June 2021. The bibliographies of included articles were reviewed to identify other potentially relevant publications. Quality assessment of the included studies was conducted. RESULTS: The review identified 19 studies assessing the economic burden and 10 studies assessing the humanistic burden of TNBC. Studies varied widely in study design, settings, patient populations, and time horizons. The estimates of mean per-patient annual direct medical costs ranged from around $20,000 to over $100,000 in stage I–III TNBC and from $100,000 to $300,000 in stage IV TNBC. Healthcare costs and resource utilization increased significantly with disease recurrence, progression, and increased cancer stage or line of therapy. Compared with the costs of systemic anticancer therapy, cancer management costs comprised a larger portion of total direct costs. The estimates of indirect costs due to productivity loss ranged from $207 to $1573 per patient per month (all costs presented above were adjusted to 2021 US dollars). Cancer recurrence led to significantly reduced productivity and greater rates of leaving the workforce. A rapid deterioration of health utility associated with disease progression was observed in TNBC patients. Treatment with pembrolizumab or talazoparib showed significantly greater improvements in health-related quality of life (HRQoL) compared with chemotherapy, as measured by EORTC QLQ-C30, QLQ-BR23, and FACT-B. CONCLUSION: TNBC is associated with a substantial economic burden on healthcare systems and societies and considerably reduced productivity and HRQoL for patients. This study synthesized the published literature on the economic and humanistic burden of TNBC and highlighted the need for continued research due to the rapidly changing landscape of TNBC care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01121-7. |
format | Online Article Text |
id | pubmed-9095534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-90955342022-05-13 Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review Huang, Min Haiderali, Amin Fox, Grace E. Frederickson, Andrew Cortes, Javier Fasching, Peter A. O’Shaughnessy, Joyce Pharmacoeconomics Systematic Review BACKGROUND: Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers (BCs). It is more commonly diagnosed in younger women and often has a less favorable prognosis compared with other BC subtypes. OBJECTIVE: The objective of this study was to provide a literature-based extensive overview of the economic and humanistic burden of TNBC to assist medical decisions for healthcare payers, providers, and patients. METHODS: A systematic literature review was performed using multiple databases, including EMBASE, MEDLINE, Econlit, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from database inception to 16 May 2021. In addition, a targeted search was performed in the Northern Light Life Sciences Conference Abstracts database from 2016 through June 2021. The bibliographies of included articles were reviewed to identify other potentially relevant publications. Quality assessment of the included studies was conducted. RESULTS: The review identified 19 studies assessing the economic burden and 10 studies assessing the humanistic burden of TNBC. Studies varied widely in study design, settings, patient populations, and time horizons. The estimates of mean per-patient annual direct medical costs ranged from around $20,000 to over $100,000 in stage I–III TNBC and from $100,000 to $300,000 in stage IV TNBC. Healthcare costs and resource utilization increased significantly with disease recurrence, progression, and increased cancer stage or line of therapy. Compared with the costs of systemic anticancer therapy, cancer management costs comprised a larger portion of total direct costs. The estimates of indirect costs due to productivity loss ranged from $207 to $1573 per patient per month (all costs presented above were adjusted to 2021 US dollars). Cancer recurrence led to significantly reduced productivity and greater rates of leaving the workforce. A rapid deterioration of health utility associated with disease progression was observed in TNBC patients. Treatment with pembrolizumab or talazoparib showed significantly greater improvements in health-related quality of life (HRQoL) compared with chemotherapy, as measured by EORTC QLQ-C30, QLQ-BR23, and FACT-B. CONCLUSION: TNBC is associated with a substantial economic burden on healthcare systems and societies and considerably reduced productivity and HRQoL for patients. This study synthesized the published literature on the economic and humanistic burden of TNBC and highlighted the need for continued research due to the rapidly changing landscape of TNBC care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01121-7. Springer International Publishing 2022-02-03 2022 /pmc/articles/PMC9095534/ /pubmed/35112331 http://dx.doi.org/10.1007/s40273-021-01121-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Systematic Review Huang, Min Haiderali, Amin Fox, Grace E. Frederickson, Andrew Cortes, Javier Fasching, Peter A. O’Shaughnessy, Joyce Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review |
title | Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review |
title_full | Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review |
title_fullStr | Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review |
title_full_unstemmed | Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review |
title_short | Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review |
title_sort | economic and humanistic burden of triple-negative breast cancer: a systematic literature review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095534/ https://www.ncbi.nlm.nih.gov/pubmed/35112331 http://dx.doi.org/10.1007/s40273-021-01121-7 |
work_keys_str_mv | AT huangmin economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview AT haideraliamin economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview AT foxgracee economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview AT fredericksonandrew economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview AT cortesjavier economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview AT faschingpetera economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview AT oshaughnessyjoyce economicandhumanisticburdenoftriplenegativebreastcancerasystematicliteraturereview |